205 related articles for article (PubMed ID: 35169804)
1. Targeted isolation of panels of diverse human protective broadly neutralizing antibodies against SARS-like viruses.
He WT; Musharrafieh R; Song G; Dueker K; Tse LV; Martinez DR; Schäfer A; Callaghan S; Yong P; Beutler N; Torres JL; Volk RM; Zhou P; Yuan M; Liu H; Anzanello F; Capozzola T; Parren M; Garcia E; Rawlings SA; Smith DM; Wilson IA; Safonova Y; Ward AB; Rogers TF; Baric RS; Gralinski LE; Burton DR; Andrabi R
bioRxiv; 2022 Feb; ():. PubMed ID: 35169804
[TBL] [Abstract][Full Text] [Related]
2. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses.
He WT; Musharrafieh R; Song G; Dueker K; Tse LV; Martinez DR; Schäfer A; Callaghan S; Yong P; Beutler N; Torres JL; Volk RM; Zhou P; Yuan M; Liu H; Anzanello F; Capozzola T; Parren M; Garcia E; Rawlings SA; Smith DM; Wilson IA; Safonova Y; Ward AB; Rogers TF; Baric RS; Gralinski LE; Burton DR; Andrabi R
Nat Immunol; 2022 Jun; 23(6):960-970. PubMed ID: 35654851
[TBL] [Abstract][Full Text] [Related]
3. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening.
Yang X; Duan H; Liu X; Zhang X; Pan S; Zhang F; Gao P; Liu B; Yang J; Chi X; Yang W
J Virol; 2023 Jul; 97(7):e0061023. PubMed ID: 37367229
[TBL] [Abstract][Full Text] [Related]
4. Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses.
Wang Y; Liu M; Shen Y; Ma Y; Li X; Zhang Y; Liu M; Yang XL; Chen J; Yan R; Luan D; Wang Y; Chen Y; Wang Q; Lin H; Li Y; Wu K; Zhu T; Zhao J; Lu H; Wen Y; Jiang S; Wu F; Zhou Q; Shi ZL; Huang J
Cell Discov; 2022 Apr; 8(1):36. PubMed ID: 35443747
[TBL] [Abstract][Full Text] [Related]
5. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease.
Zhou P; Song G; Liu H; Yuan M; He WT; Beutler N; Zhu X; Tse LV; Martinez DR; Schäfer A; Anzanello F; Yong P; Peng L; Dueker K; Musharrafieh R; Callaghan S; Capozzola T; Limbo O; Parren M; Garcia E; Rawlings SA; Smith DM; Nemazee D; Jardine JG; Safonova Y; Briney B; Rogers TF; Wilson IA; Baric RS; Gralinski LE; Burton DR; Andrabi R
Immunity; 2023 Mar; 56(3):669-686.e7. PubMed ID: 36889306
[TBL] [Abstract][Full Text] [Related]
6. Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2: Implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies.
Li S; Wu J; Jiang W; He H; Zhou Y; Wu W; Gao Y; Xie M; Xia A; He J; Zhang Q; Han Y; Wang N; Zhu G; Wang Q; Zhang Z; Mayer CT; Wang K; Wang X; Wang J; Chen Z; Jiang S; Sun L; Xia R; Wang Q
J Med Virol; 2023 Feb; 95(2):e28440. PubMed ID: 36573441
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
Jensen JL; Sankhala RS; Dussupt V; Bai H; Hajduczki A; Lal KG; Chang WC; Martinez EJ; Peterson CE; Golub ES; Rees PA; Mendez-Rivera L; Zemil M; Kavusak E; Mayer SV; Wieczorek L; Kannan S; Doranz BJ; Davidson E; Yang ES; Zhang Y; Chen M; Choe M; Wang L; Gromowski GD; Koup RA; Michael NL; Polonis VR; Rolland M; Modjarrad K; Krebs SJ; Joyce MG
J Virol; 2023 Jul; 97(7):e0159622. PubMed ID: 37395646
[TBL] [Abstract][Full Text] [Related]
8. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979
[TBL] [Abstract][Full Text] [Related]
9. Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motif.
Hauser BM; Sangesland M; Lam EC; Denis KJS; Feldman J; Yousif AS; Caradonna TM; Kannegieter T; Balazs AB; Lingwood D; Schmidt AG
bioRxiv; 2021 Jun; ():. PubMed ID: 33330872
[TBL] [Abstract][Full Text] [Related]
10. Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates.
Malewana RD; Stalls V; May A; Lu X; Martinez DR; Schäfer A; Li D; Barr M; Sutherland LL; Lee E; Parks R; Beck WE; Newman A; Bock KW; Minai M; Nagata BM; DeMarco CT; Denny TN; Oguin TH; Rountree W; Wang Y; Mansouri K; Edwards RJ; Sempowski GD; Eaton A; Muramatsu H; Henderson R; Tam Y; Barbosa C; Tang J; Cain DW; Santra S; Moore IN; Andersen H; Lewis MG; Golding H; Seder R; Khurana S; Montefiori DC; Pardi N; Weissman D; Baric RS; Acharya P; Haynes BF; Saunders KO
bioRxiv; 2023 Dec; ():. PubMed ID: 38187726
[TBL] [Abstract][Full Text] [Related]
11. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
[TBL] [Abstract][Full Text] [Related]
12. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
[TBL] [Abstract][Full Text] [Related]
13. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
[TBL] [Abstract][Full Text] [Related]
14. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
15. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
16. Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift.
Song G; Yuan M; Liu H; Capozzola T; Lin RN; Torres JL; He WT; Musharrafieh R; Dueker K; Zhou P; Callaghan S; Mishra N; Yong P; Anzanello F; Avillion G; Vo AL; Li X; Makhdoomi M; Feng Z; Zhu X; Peng L; Nemazee D; Safonova Y; Briney B; Ward AB; Burton DR; Wilson IA; Andrabi R
bioRxiv; 2023 Apr; ():. PubMed ID: 37162858
[TBL] [Abstract][Full Text] [Related]
17. Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2.
Feng Y; Yuan M; Powers JM; Hu M; Munt JE; Arunachalam PS; Leist SR; Bellusci L; Adams LE; Sundaramurthy S; Shirreff LM; Mallory ML; Scooby TD; Moreno A; O'Hagan DT; Kleanthous H; Villinger FJ; Veesler D; King NP; Suthar MS; Khurana S; Baric RS; Wilson IA; Pulendran B
bioRxiv; 2023 Jan; ():. PubMed ID: 36711543
[TBL] [Abstract][Full Text] [Related]
18. Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination.
Chi X; Guo Y; Zhang G; Sun H; Zhang J; Li M; Chen Z; Han J; Zhang Y; Zhang X; Fan P; Zhang Z; Wang B; Zai X; Han X; Hao M; Fang T; Xu J; Wu S; Chen Y; Fang Y; Dong Y; Sun B; Zhang J; Li J; Zhao G; Yu C; Zhou Q; Chen W
Signal Transduct Target Ther; 2022 Apr; 7(1):139. PubMed ID: 35478188
[TBL] [Abstract][Full Text] [Related]
19. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses.
Li M; Ren Y; Aw ZQ; Chen B; Yang Z; Lei Y; Cheng L; Liang Q; Hong J; Yang Y; Chen J; Wong YH; Wei J; Shan S; Zhang S; Ge J; Wang R; Dong JZ; Chen Y; Shi X; Zhang Q; Zhang Z; Chu JJH; Wang X; Zhang L
Nat Commun; 2022 Dec; 13(1):7957. PubMed ID: 36575191
[TBL] [Abstract][Full Text] [Related]
20. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
